AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05165875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Splint
Description: Intervention will be done on the same day based on the randomization. For the splint group, a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks. Subsequently, the splint will be weaned and passive range of motion exercises taught.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants.
Study NCT06129695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zygomatic implants
Description: the ideal way to support implant-based restorative procedures for full and partially edentulous patients who are missing bone in the upper posterior maxilla.
Study NCT06129695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zygomatic implants
Description: the ideal way to support implant-based restorative procedures for full and partially edentulous patients who are missing bone in the upper posterior maxilla.
Study NCT06393127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 Formulation C2
Description: BI 1015550 Formulation C2
Study NCT06393127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 Formulation C1
Description: BI 1015550 Formulation C1
Study NCT06529094 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider training
Description: Provider participants will complete TMS training, CAPP-FIT demonstration and simulation in use of the CAPP-FIT with a standardized patient.
Study NCT06529094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAPP-FIT intervention with RA facilitation
Description: After consent and survey completion, RA to email/text CAPP-FIT link to Veteran the day before established clinic visit. RA to remain available to answer questions to help Veteran participant complete Veteran Survey and submit the responses through eScreening. The Provider Report will appear in CPRS with a Provider notification. RA to meet Veteran participant in the clinic after the clinic visit to complete the Veteran satisfaction survey.
Study NCT06529094 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CAPP-FIT implementation during maintenance phase
Description: Providers will attend focus group after Arm 2 to determine sustainability of CAPP-FIT use in clinic workflow. Clinic provider will act on that determination for 10 months during maintenance phase.
Study NCT05580458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix
Description: Shingrix is a recombinant, adjuvanted vaccine for prevention of herpes zoster. It is supplied as lyophilized recombinant VZV surface gE antigen for reconstitution with AS01B adjuvant suspension. Each Shingrix dose will be 0.5mL and administered by IM injection in the deltoid region of the upper arm.
Study NCT05802550 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ocular Surface Disease Index
Description: Questionnaire on ocular surface disorders
Study NCT05802550 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interferometry
Description: Non-contact examination measuring NIBUT (non-invasive break-up time), meibography and tear meniscus measurement
Study NCT05802550 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oxford score
Description: Investigation and quantification of superficial corneal punctate keratitis using the Oxford score
Study NCT05802550 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conjunctival collection
Description: Two conjunctival prints: one for metabolomic and one for lipidomic
Study NCT05802550 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aqueous humor collection
Description: Collection of 0.1 mL of aqueous humor immediately after making the accessory corneal incision at the beginning of the cataract surgery.
Study NCT05802550 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quantification of Tyndall and flare
Description: Quantification of Tyndall and flare (from 1 to 4 crosses) in anterior chamber
Study NCT05353543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
Study NCT05353543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture (strong reaction acupoints)
Description: This study will use the intradermal needle as an acupuncture intervention. Strong reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
Study NCT05353543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture (weak reaction acupoints)
Description: This study will use the intradermal needle as an acupuncture intervention. Weak reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
Study NCT05353543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sham acupuncture
Description: Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to strong reaction acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
Study NCT05838521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
Study NCT06637436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: This telehealth MI intervention seeks to increase intrinsic motivation and self-efficacy for starting or restarting pre-exposure prophylaxis (PrEP) in session one. Session two focuses on concomitant risk behaviors such as substance use and CAS.
Study NCT06637436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: Provides incentives for initiating PrEP care ($50) and filling a PrEP prescription ($50) in the three months following randomization.
Study NCT06534502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide Oral Product
Description: Zonisamide oral suspension
Study NCT05375292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREHABILITATION
Description: Customized program made by the physical therapist based on the first visit.~It includes 3 parts :~1. Nutrition advices that ensures adequate caloric and protein intake to support muscle anabolism~2. Muscle building over a few sessions with a physiotherapist to learn exercises and then independently redo them~3. Cardio-respiratory endurance exercises.
Study NCT06243848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Incision Surgery for median nerve decompression
Description: Classic minimal incision surgical technique for median nerve decompression in patients diagnosed with mild, moderate, and severe carpal tunnel syndrome.
Study NCT06243848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided perineural injection with 5 cc 5% Dextrose
Description: The median nerve will be identified using ultrasound at the proximal entrance of the carpal tunnel. Using an ulnar approach with the in-plane technique, it was planned to inject 5 cc of 5% dextrose around the median nerve.
Study NCT06080737 — intervention group
Intervention type: OTHER
Intervention: quality of life questionnaire
Description: telephone interview to assess mortality and quality of life in the population included in a trial
Study NCT06186700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxiphylline tablets three times per day for the treatment period of neoadjuvant chemotherapy cycles of doxorubicin/ cyclophosphamide
Study NCT06186700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets three times per day for the treatment period of neoadjuvant chemotherapy cycles of doxorubicin/ cyclophosphamide
Study NCT05284032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab 10 mg/kg
Description: Given by intravenous infusion
Study NCT05147246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentCorps-Professional Development (PD)
Description: PD is a school-based evidence-based-intervention (EBI) and preventive service provision model that supports teachers and school personnel to apply EBI strategies to promot young children's medical health in impoverished areas. Teachers and PTAs will participate in a 4-day training before the 1st school term. Teachers in the intervention condition will also receive 8 sessions (8 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
Study NCT05200988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab + nivolumab
Description: Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~* Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~* Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy
Study NCT05272514 — intervention group
Intervention type: OTHER
Intervention: Hypoxia
Description: Individuals will be exposed to varying levels of hypoxia according to the protocol detailed above.
Study NCT03332888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be studied in patients with HFrEF, and verify the patients safety.
Study NCT05712824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-LAP™ SYSTEM
Description: Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
Study NCT06098014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide Capsules
Description: To see safety and efficacy of Thalidomide in Transfusion depended thalassemia
Study NCT06098014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: compare with Thalidomide
Study NCT05564858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia
Description: FDA022-BB05, intravenously infusion, q3w
Study NCT05564858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib
Description: FDA022-BB05, intravenously infusion, q3w
Study NCT06260787 — intervention group
Intervention type: PROCEDURE
Intervention: In Vitro Fertilisation
Description: Assisted reproductive technology in the form of in vitro fertilisation
Study NCT05388357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Procedure: PCI
Description: Percutaneous Coronary Intervention
Study NCT05388357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Procedure: PCI
Description: Percutaneous Coronary Intervention
Study NCT05887635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Vapor Ablation
Description: RF Vapor ablation of the duodenum
Study NCT05803941 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AAA617
Description: Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent clinical interventional Novartis sponsored clinical trials.
Study NCT05613270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FES PET/CT scan
Description: Patients with suspected metastatic ER-positive breast cancer underwent 18F-FES PET/CT after an injection of 185-222 MBq (5-6 mCi) 18F-FES to image lesions of metastatic breast cancer.
Study NCT06332443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Spinal anesthesia will be performed in the sitting or lateral position under sterile conditions. Spinal puncture will be performed at L2-L4 level using 50 mg of Clorotekal 1 or 2%. (intermediate-acting amide local anesthesia, commonly used) will be injected.
Study NCT06332443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation epidural anesthesia
Description: Sedation-EA will be performed in the sitting or lateral position under sterile conditions. Epidural puncture will be performed at the L2-L4 level and an epidural catheter will be inserted into the epidural space. 10 ml of 2% xylocaine without epinephrine will be injected through the catheter and the dose will be titrated (up to 20 mL) to achieve complete sensory block up to T12 dermatoma measured with a level to ice.
Study NCT05549388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-pack labeling
Description: The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.
Study NCT04880811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib is orally administered at 40mg Qd of each 21 day cycle.
Study NCT04880811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.
Study NCT06165367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EmbryoGlue Medium
Description: Embryos will be exposed to hyaluronic-enriched media (EmbryoGlue) before and during embryo transfer
Study NCT04747535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-CPAP
Description: AIrSense 10, Auto-CPAP, Minimum pressure 5 cm water, maximum pressure 10 cm water
Study NCT04747535 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP since before
Description: A CPAP the patient uses since before because of previously diagnosed obstructive sleep apnea
Study NCT05163743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Calorie Ketogenic Diet
Description: The very low-carbohydrate diet will be hypo caloric and aim to provide less than 50 g of carbohydrates per day. the participants will be counseled to choose vegetarian and healthy sources of fat and protein and to avoid trans fat. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
Study NCT04704531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Ophthalmic 0.4% BID
Description: Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.
Study NCT04704531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Ophthalmic 0.4% QID
Description: Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.
Study NCT04704531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Ophthalmic 0.4% Six times per day
Description: Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.
Study NCT02930447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous glue
Description: Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
Study NCT05910398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyrotinib
Description: an irreversible anti-HER2 tyrosine kinase inhibitor
Study NCT05910398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: an irreversible anti-HER2 tyrosine kinase inhibitor
Study NCT04995159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single anti-platelet therapy
Description: Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.
Study NCT04995159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual anti-platelet therapy
Description: Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.
Study NCT05588219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab injection\[10ml:100mg\] will be used beginning with radiotherapy: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
Study NCT05588219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP synchronous with radiotherapy
Description: DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.
Study NCT04614051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram-DC
Description: Patients will receive 3 times every 2 weeks injection of Cellgram-DC(Autologous dendritic cell) subcutaneous injection near the upper arm lymph nodes
Study NCT04781920 — intervention group
Intervention type: OTHER
Intervention: datas collection
Description: data collection in history medical : operative report, clinical examination, questionnaires, imaging, isokinetic tests
Study NCT06114901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SleepFix
Description: SleepFix mobile application uses Sleep Retraining Therapy (SRT) which aims to reduce excess time spent in bed and reset sleep by matching time in bed (minimum of five and a half hours) to total sleep time (TST). There are four stages to the dBTi application and participants will progress based on completion of each stage. At the commencement of SleepFix application, participants enter sleep and bedtime data into the smartphone application for baseline referencing. These data are used to determine the sleep therapy based on a pre-determined algorithm that calculates optimum sleep efficiency.
Study NCT06114901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep health Education modules
Description: Three Sleep Health education modules that contain information about sleep hygiene and introduces strategies on how to reduce insomnia severity and increase sleep quality.
Study NCT06307860 — intervention group
Intervention type: DEVICE
Intervention: pulsed field ablation
Description: Selected patients were selected to undergo relevant surgeries, and their preoperative and postoperative baseline data were collected. They were followed up for 6 months after surgery.
Study NCT06307860 — intervention group
Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: Selected patients were selected to undergo relevant surgeries, and their preoperative and postoperative baseline data were collected. They were followed up for 6 months after surgery.
Study NCT06280586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Description: * bimonthly personalized follow-up with the appropriate specialists (5 in a year) i~* a program of group activities (6 sessions in a year) with a monitor with the aim of reinforcing adherence to the study intervention and adapting it to the circumstances and the physical, personal and social reality around each participant. The sessions will last approximately one hour and will cover:~  * General dietary and hydration recommendations and dietary recommendations for people at risk of malnutrition~ * Dietary and physical exercise recommendations in obese elderly~ * General physical exercise recommendations in the elderly and physical exercise recommendations in the elderly with sarcopenia~ * Physical exercise recommendations for the elderly at risk of falls.~ * Medication management and social resources for the elderly in Mataró.